CA2221710A1 - Therapie genique pour ischemie myocardique - Google Patents
Therapie genique pour ischemie myocardique Download PDFInfo
- Publication number
- CA2221710A1 CA2221710A1 CA 2221710 CA2221710A CA2221710A1 CA 2221710 A1 CA2221710 A1 CA 2221710A1 CA 2221710 CA2221710 CA 2221710 CA 2221710 A CA2221710 A CA 2221710A CA 2221710 A1 CA2221710 A1 CA 2221710A1
- Authority
- CA
- Canada
- Prior art keywords
- vector
- adenoviral
- transgene
- plasmid
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 16
- 238000001415 gene therapy Methods 0.000 title abstract description 7
- 239000013598 vector Substances 0.000 claims abstract description 93
- 210000004027 cell Anatomy 0.000 claims abstract description 86
- 210000004413 cardiac myocyte Anatomy 0.000 claims abstract description 27
- 238000002347 injection Methods 0.000 claims abstract description 27
- 239000007924 injection Substances 0.000 claims abstract description 27
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 17
- 238000001727 in vivo Methods 0.000 claims abstract description 16
- 230000003612 virological effect Effects 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 40
- 230000002107 myocardial effect Effects 0.000 claims description 38
- 108700019146 Transgenes Proteins 0.000 claims description 34
- 239000013612 plasmid Substances 0.000 claims description 32
- 210000004165 myocardium Anatomy 0.000 claims description 29
- 210000002216 heart Anatomy 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 23
- 230000000747 cardiac effect Effects 0.000 claims description 20
- 230000002950 deficient Effects 0.000 claims description 14
- 230000010076 replication Effects 0.000 claims description 13
- 230000000250 revascularization Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 10
- 241001135569 Human adenovirus 5 Species 0.000 claims description 9
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 8
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 8
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims description 8
- 102100039165 Heat shock protein beta-1 Human genes 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 238000005215 recombination Methods 0.000 claims description 8
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 claims description 7
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 102000008161 Adenosine A3 Receptor Human genes 0.000 claims description 5
- 108010060261 Adenosine A3 Receptor Proteins 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 230000000644 propagated effect Effects 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000002586 coronary angiography Methods 0.000 claims description 4
- 230000000120 cytopathologic effect Effects 0.000 claims description 4
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 claims description 4
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 claims description 3
- 101100462537 Caenorhabditis elegans pac-1 gene Proteins 0.000 claims description 3
- 101100117764 Mus musculus Dusp2 gene Proteins 0.000 claims description 3
- 229920002684 Sepharose Polymers 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 108010067770 Endopeptidase K Proteins 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 101150075174 E1B gene Proteins 0.000 claims 6
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 claims 3
- 238000007675 cardiac surgery Methods 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001902 propagating effect Effects 0.000 claims 2
- 238000012869 ethanol precipitation Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000005199 ultracentrifugation Methods 0.000 claims 1
- 230000001681 protective effect Effects 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 95
- 238000012546 transfer Methods 0.000 description 28
- 208000028867 ischemia Diseases 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- 241000701161 unidentified adenovirus Species 0.000 description 22
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 210000000107 myocyte Anatomy 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 102000004420 Creatine Kinase Human genes 0.000 description 12
- 108010042126 Creatine kinase Proteins 0.000 description 12
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 11
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 11
- 230000000302 ischemic effect Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000001262 western blot Methods 0.000 description 7
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 6
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 6
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 108010016628 ameroid Proteins 0.000 description 6
- 230000003466 anti-cipated effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 101150066555 lacZ gene Proteins 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101150031823 HSP70 gene Proteins 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 101150052825 dnaK gene Proteins 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 101710159527 Maturation protein A Proteins 0.000 description 2
- 101710091157 Maturation protein A2 Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 101150107341 RERE gene Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000002530 ischemic preconditioning effect Effects 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 101150044182 8 gene Proteins 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 1
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 101150104791 MYOC gene Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical class [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 241001024099 Olla Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 150000002658 luteins Chemical class 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Utilisation efficace du vecteur adénoviral présentant un déficit de réplication et inséré par transgène en thérapie génique in vivo pour protéger de l'ischémie myocardique, par une seule injection intracoronaire, directement introduite profondément dans la lumière des artères coronaires, en une quantité suffisante pour transfecter tous les types de cellules dans la région affectée, y compris les myocytes cardiaques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48112295A | 1995-06-07 | 1995-06-07 | |
| US08/481,122 | 1995-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2221710A1 true CA2221710A1 (fr) | 1996-12-19 |
Family
ID=23910695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2221710 Abandoned CA2221710A1 (fr) | 1995-06-07 | 1996-06-07 | Therapie genique pour ischemie myocardique |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0831874A4 (fr) |
| AU (1) | AU6268196A (fr) |
| CA (1) | CA2221710A1 (fr) |
| WO (1) | WO1996040195A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| US7627373B2 (en) | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
| WO2009105135A1 (fr) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions pour un captage amélioré de vecteurs viraux dans le myocarde |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346812A (en) * | 1989-09-07 | 1994-09-13 | The University Of Miami | Teratogen assay |
| US5071962A (en) * | 1990-05-31 | 1991-12-10 | The United State Of America As Represented By The Department Of Health And Human Services | Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins |
| US5443836A (en) * | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
-
1996
- 1996-06-07 CA CA 2221710 patent/CA2221710A1/fr not_active Abandoned
- 1996-06-07 EP EP96921461A patent/EP0831874A4/fr not_active Withdrawn
- 1996-06-07 AU AU62681/96A patent/AU6268196A/en not_active Abandoned
- 1996-06-07 WO PCT/US1996/009858 patent/WO1996040195A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU6268196A (en) | 1996-12-30 |
| EP0831874A1 (fr) | 1998-04-01 |
| EP0831874A4 (fr) | 2002-03-06 |
| WO1996040195A1 (fr) | 1996-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU706908B2 (en) | Gene-transfer-mediated angiogenesis therapy | |
| US6174871B1 (en) | Gene therapies for enhancing cardiac function | |
| Quantin et al. | Adenovirus as an expression vector in muscle cells in vivo. | |
| French et al. | Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. | |
| Chen et al. | Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. | |
| Kaplitt et al. | Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector | |
| JP3487597B2 (ja) | 筋細胞内での発現のためのウイルス性組換え型ベクター | |
| Lee et al. | Cardiac gene transfer by intracoronary infusion of adenovirus vector—mediated reporter gene in the transplanted mouse heart | |
| EP1695719A1 (fr) | Combinaision d'une acide nucléaire et d'un agent vasoactif pour l'amélioration de transfert de gènes | |
| EA005157B1 (ru) | Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов | |
| US20040132190A1 (en) | Gene therapy for myocardial ischemia | |
| Rowland et al. | Potential gene therapy strategies in the treatment of cardiovascular disease | |
| AU2001283108A1 (en) | Manipulation of arterial-venous identity | |
| CA2221710A1 (fr) | Therapie genique pour ischemie myocardique | |
| US6743623B2 (en) | Viral recombinant vectors for expression in muscle cells | |
| US6099831A (en) | Viral recombinant vectors for expression in muscle cells | |
| AU706050C (en) | Gene transfer-mediated angiogenesis therapy | |
| AU2006200170B2 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| Yamaguchi et al. | Adenovirus-mediated insulin gene transfer improves nutritional and post-hepatectomized conditions in diabetic rats | |
| AU4754199A (en) | Gene transfer-mediated angiogenesis therapy | |
| AU2006235836A1 (en) | Gene transfer-mediated angiogenesis therapy | |
| Taylor et al. | Skeletal myoblast therapy in cardiovascular disease | |
| HK1094944A (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| HK1008979B (en) | Gene transfer-mediated angiogenesis therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |